{"meta":{"query_hash":"78c2101363ae","filters":{"venue":"Clinical Lymphoma & Myeloma"},"cohort_total":13,"direct_labels_cover":0,"predictions_cover":13,"exported":13,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/78c2101363ae","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Lymphoma+%26+Myeloma"},"results":[{"id":"W1965861190","doi":"10.3816/clm.2006.s.003","title":"Treatment of Diffuse Large B-Cell Lymphoma: A Risk-Based Approach","year":2006,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"International Prognostic Index; Rituximab; Medicine; Diffuse large B-cell lymphoma; Context (archaeology); Oncology; Prednisone; Lymphoma; Vincristine; Internal medicine; CHOP; Cyclophosphamide; Clinical trial; Intensive care medicine; Chemotherapy; Biology","score_opus":0.06659608710929593,"score_gpt":0.373539151332449,"score_spread":0.3069430642231531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965861190","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001550363,0.9985727,0.00030962296,0.00027393692,0.00009424299,0.0000058282417,0.000009265699,0.000009026509,0.00057035533],"genre_scores_gemma":[0.0018530006,0.99660254,0.0006662146,0.00035260315,0.00019098473,0.000007358018,0.000028095157,0.0000017720804,0.0002973413],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997507,0.00005503525,0.0000427181,0.000047557416,0.00008693482,0.000017186418],"domain_scores_gemma":[0.9997247,0.0001475475,0.000055542947,0.0000060635225,0.0000486367,0.000017553133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005395619,0.0009669366,0.0024136708,0.0019044608,0.00022167114,0.00084264274,0.0013560583,0.0009356114,0.0020261575],"category_scores_gemma":[0.0007105874,0.00024406382,0.0009711994,0.0011876662,0.00038435875,0.00087022106,0.00049622345,0.0016276955,0.00074426224],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010807578,0.0001292266,0.0004660726,0.012391027,0.0002768173,0.00045587626,0.00002872202,0.00068748987,0.0008423226,0.0014646379,0.015860135,0.9672897],"study_design_scores_gemma":[0.00030210515,0.00060971826,0.0077630803,0.01995183,0.0023433322,0.012950948,0.00018773599,0.0008770453,0.0011097031,0.0045016543,0.9493135,0.00008944719],"about_ca_topic_score_codex":0.0011609442,"about_ca_topic_score_gemma":0.0024420866,"teacher_disagreement_score":0.0024136708,"about_ca_system_score_codex":0.00074614806,"about_ca_system_score_gemma":0.00076280185,"threshold_uncertainty_score":0.00677824},"labels":[],"label_agreement":null},{"id":"W1983399256","doi":"10.3816/clm.2007.s.005","title":"The Challenges of Targeting Chronic Myeloid Leukemia Stem Cells","year":2007,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; University of British Columbia; Canada Research Chairs; Leukemia and Lymphoma Society of Canada; Michael Smith Health Research BC; Terry Fox Foundation; Cancer Research Society","keywords":"Myeloid leukemia; Stem cell; Cancer research; Leukemia; Medicine; Biology; Immunology; Cell biology","score_opus":0.09710067136416807,"score_gpt":0.3856242570326927,"score_spread":0.28852358566852465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983399256","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011970683,0.99593735,0.00021140566,0.0014169945,0.00043943644,0.0000057261686,0.000014143833,0.000009528304,0.0018458264],"genre_scores_gemma":[0.0006429321,0.9961467,0.00041858517,0.001049688,0.00038845476,0.000010826269,0.000025220897,0.0000018647293,0.0013158215],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997458,0.00005387465,0.000023425113,0.00003496612,0.000116220515,0.00002567772],"domain_scores_gemma":[0.9995233,0.00023496154,0.000051465464,0.000013089064,0.00013822099,0.000038992035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010956591,0.0008172313,0.0016378952,0.0013648857,0.0003910532,0.0013839838,0.0008262891,0.0015369377,0.003637592],"category_scores_gemma":[0.00089597364,0.00026118284,0.00050597044,0.0014585868,0.0006178036,0.0018579157,0.0008017008,0.0025987495,0.0019836249],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071232294,0.000073580544,0.00012663385,0.0050710454,0.00005674423,0.00013235255,0.00003818033,0.0004292994,0.0012425105,0.00590412,0.06574191,0.92111236],"study_design_scores_gemma":[0.000025353918,0.00006822331,0.00025420534,0.0013869887,0.000054187436,0.00046966368,0.00004221036,0.00009786359,0.00030442132,0.0015221487,0.9957657,0.000008955952],"about_ca_topic_score_codex":0.001594171,"about_ca_topic_score_gemma":0.004658175,"teacher_disagreement_score":0.003637592,"about_ca_system_score_codex":0.00093082944,"about_ca_system_score_gemma":0.0016772544,"threshold_uncertainty_score":0.012168944},"labels":[],"label_agreement":null},{"id":"W1997044577","doi":"10.3816/clm.2009.n.003","title":"Novel Aspects Pertaining to the Relationship of Waldenström's Macroglobulinemia, IgM Monoclonal Gammopathy of Undetermined Significance, Polyclonal Gammopathy, and Hypoglobulinemia","year":2009,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Cancerfonden; McMaster University","keywords":"Monoclonal gammopathy of undetermined significance; Macroglobulinemia; Waldenstrom macroglobulinemia; Gammopathy; Medicine; Immunology; Immunoglobulin M; Polyclonal antibodies; Antibody; Etiology; Population; Monoclonal; Pathology; Multiple myeloma; Immunoglobulin G; Monoclonal antibody; Lymphoma","score_opus":0.05563567867414868,"score_gpt":0.3574969234013634,"score_spread":0.3018612447272147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997044577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7694683,0.1510366,0.008856846,0.02218135,0.003214284,0.000092652765,0.00046166044,0.000077150275,0.044611074],"genre_scores_gemma":[0.96915764,0.01671172,0.0023840542,0.0015977509,0.007849629,0.000032480177,0.0002332354,0.000008880516,0.00202455],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.99975425,0.00009619226,0.000033280336,0.000037223686,0.00003314796,0.000045902863],"domain_scores_gemma":[0.9987662,0.00081796275,0.00015465192,0.00010534634,0.00009078616,0.000065025415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089898333,0.00025689302,0.00039627816,0.0009351261,0.00051470683,0.0014298141,0.00082809885,0.0011594003,0.0026758015],"category_scores_gemma":[0.0026149235,0.00020550049,0.0002831962,0.000638156,0.0016192248,0.0016500329,0.0005190765,0.0010402981,0.00036207057],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053850664,0.0011376572,0.1528416,0.0019403042,0.0004817282,0.2592913,0.0034464735,0.00215514,0.14402258,0.18356395,0.016610945,0.22912328],"study_design_scores_gemma":[0.0005206494,0.0016471327,0.17660724,0.0003353941,0.0007738634,0.46774432,0.0040296316,0.005210004,0.033452738,0.17525887,0.1342785,0.00014161272],"about_ca_topic_score_codex":0.00039804744,"about_ca_topic_score_gemma":0.0005069557,"teacher_disagreement_score":0.0026758015,"about_ca_system_score_codex":0.0003912999,"about_ca_system_score_gemma":0.00032653354,"threshold_uncertainty_score":0.008951426},"labels":[],"label_agreement":null},{"id":"W1999005132","doi":"10.3816/clm.2009.n.001","title":"Advances in the Biology and Treatment of Waldenström's Macroglobulinemia: A Report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden","year":2009,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University; International Waldenstrom's Macroglobulinemia Foundation","keywords":"Waldenstrom macroglobulinemia; Macroglobulinemia; Medicine; Immunology; Lymphoma; Multiple myeloma","score_opus":0.0522128022844153,"score_gpt":0.42570897067548746,"score_spread":0.37349616839107214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999005132","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032171966,0.96022666,0.0008807782,0.02422294,0.008128035,0.00006182094,0.00014191796,0.000026813217,0.0030937898],"genre_scores_gemma":[0.019666707,0.9508648,0.0022431621,0.008452617,0.012204564,0.00009996662,0.0005127749,0.000031447522,0.0059239343],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979107,0.0005397689,0.00025190916,0.00016040857,0.000649932,0.00048722525],"domain_scores_gemma":[0.9966737,0.0013276109,0.00017622534,0.00007746107,0.0011147719,0.0006301691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011315231,0.0011250328,0.0012020853,0.0021356712,0.00046748106,0.0030414662,0.0011031327,0.003296744,0.0027296958],"category_scores_gemma":[0.003775645,0.00040632163,0.001308789,0.0015419297,0.00090668927,0.002232504,0.001944857,0.004692331,0.0008013135],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019612147,0.00089921243,0.0033289841,0.0044469903,0.0002331598,0.0010514143,0.00057345565,0.0012026093,0.00804605,0.00414033,0.19723535,0.77688116],"study_design_scores_gemma":[0.00025701884,0.0009102946,0.0059807305,0.0015682491,0.00028355105,0.0007857504,0.00024375421,0.00014255734,0.006343204,0.0009635826,0.9824782,0.000043166594],"about_ca_topic_score_codex":0.0024503106,"about_ca_topic_score_gemma":0.005151628,"teacher_disagreement_score":0.011315231,"about_ca_system_score_codex":0.0015671097,"about_ca_system_score_gemma":0.0039103506,"threshold_uncertainty_score":0.059841335},"labels":[],"label_agreement":null},{"id":"W2029070773","doi":"10.3816/clm.2009.s.032","title":"Molecular and Genetic Bases of Myeloproliferative Disorders: Questions and Perspectives","year":2009,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Ligue Contre le Cancer; Fondation pour la Recherche Médicale; Institut National de la Santé et de la Recherche Médicale; AstraZeneca","keywords":"Essential thrombocythemia; Myelofibrosis; Polycythemia vera; Myeloproliferative Disorders; Loss of heterozygosity; Mutation; Pathogenesis; Genetics; Epigenetics; Biology; Exon; Bioinformatics; Medicine; Gene; Immunology; Allele","score_opus":0.05432203405575678,"score_gpt":0.3835875530794639,"score_spread":0.32926551902370715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029070773","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007808724,0.99846834,0.00008691071,0.00071760244,0.00015783624,0.0000017026923,0.000009772617,0.0000034125126,0.0004762412],"genre_scores_gemma":[0.00040992963,0.998727,0.00014978558,0.00027240976,0.00030252937,0.0000022976158,0.000014180866,4.4530358e-7,0.00012143931],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979943,0.000039068036,0.000035889465,0.00003699148,0.00006751355,0.000021178743],"domain_scores_gemma":[0.99939287,0.00033296034,0.00007891353,0.000016291253,0.00013899137,0.0000399332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009850303,0.0008009612,0.0020876236,0.0018720556,0.0003250554,0.0012876294,0.001237289,0.0014991959,0.003016796],"category_scores_gemma":[0.0010742545,0.00032280962,0.00052186457,0.0023022483,0.00092161016,0.0021077592,0.00068931945,0.002193638,0.0015944184],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016169358,0.00012344893,0.0007789848,0.011377883,0.00015099322,0.0010720955,0.000106411,0.00063313084,0.0025915657,0.009838871,0.048730943,0.9244339],"study_design_scores_gemma":[0.000051886735,0.000061949635,0.0017115899,0.004405413,0.00022125286,0.0040410357,0.00020387588,0.00015063878,0.00037777596,0.00780575,0.9809334,0.00003550259],"about_ca_topic_score_codex":0.0013020241,"about_ca_topic_score_gemma":0.0019128842,"teacher_disagreement_score":0.003016796,"about_ca_system_score_codex":0.00083538,"about_ca_system_score_gemma":0.0016859834,"threshold_uncertainty_score":0.010092199},"labels":[],"label_agreement":null},{"id":"W2033238287","doi":"10.3816/clm.2009.n.047","title":"von Hippel–Lindau Methylation Status in Patients with Multiple Myeloma: A Potential Predictive Factor for the Development of Bone Disease","year":2009,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Bone health and treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Disease; Medicine; Methylation; Oncology; Cancer research; Internal medicine; Pathology; Biology; Genetics; Gene","score_opus":0.026023887822227466,"score_gpt":0.3245251999379395,"score_spread":0.298501312115712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033238287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737275,0.0009255492,0.00011749971,0.00021174166,0.00000939403,0.0000044482554,0.00019745021,0.000010153088,0.0011510504],"genre_scores_gemma":[0.9994591,0.00014326409,0.00007792833,0.000023968902,0.000015748552,0.000002440581,0.00008745639,0.0000014368795,0.00018866597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99984145,0.000035662546,0.000016418597,0.00002938544,0.00004576943,0.00003128881],"domain_scores_gemma":[0.9994326,0.000202172,0.00018136343,0.00001937662,0.00005104859,0.00011344066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002558964,0.0002163841,0.00030863512,0.0007479702,0.00042713626,0.00044118857,0.0002654886,0.0005035148,0.001759204],"category_scores_gemma":[0.0013022113,0.0002068376,0.00019763396,0.00075410877,0.0002791582,0.00031719264,0.00021488528,0.00056624576,0.00019017581],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033759343,0.000031123527,0.9940865,0.000010575269,0.000035197954,0.00035112243,0.000034354507,0.00008775525,0.0020725722,0.0000426533,0.00015999313,0.0027505958],"study_design_scores_gemma":[0.000015354599,0.00013082601,0.9958806,0.0000054826673,0.000073213654,0.0018440824,0.00009053993,0.00072225253,0.0007172925,0.00015470578,0.00036153154,0.000004106696],"about_ca_topic_score_codex":0.0024773309,"about_ca_topic_score_gemma":0.0035294169,"teacher_disagreement_score":0.0024773309,"about_ca_system_score_codex":0.00030041035,"about_ca_system_score_gemma":0.0003711299,"threshold_uncertainty_score":0.005885124},"labels":[],"label_agreement":null},{"id":"W2090582753","doi":"10.3816/clm.2007.n.011","title":"Clinical Utility of Biochemical Markers of Bone Metabolism for Improving the Management of Patients with Advanced Multiple Myeloma","year":2007,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Bone health and treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program; University of Waterloo","funders":"","keywords":"Bone remodeling; Multiple myeloma; Medicine; Osteocalcin; Bone disease; Pathology; Internal medicine; Alkaline phosphatase; Osteoporosis; Biology; Biochemistry; Enzyme","score_opus":0.06308222886850288,"score_gpt":0.4007285747909416,"score_spread":0.3376463459224387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090582753","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011053042,0.9993748,0.00007543553,0.00013792263,0.000053330685,0.0000032865155,0.000011317612,0.0000032682965,0.00023014162],"genre_scores_gemma":[0.00087227614,0.99845445,0.00022148971,0.00018575843,0.000110671426,0.0000046758755,0.00003194479,7.5547393e-7,0.000118027514],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996611,0.00006785597,0.000059785798,0.000054712156,0.00013738457,0.000019077277],"domain_scores_gemma":[0.99901056,0.0005523674,0.00014916231,0.000017003716,0.00022870257,0.00004222048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010841421,0.0010938408,0.0032693862,0.0023287814,0.0001764148,0.00088555296,0.0012959365,0.001123167,0.0017515686],"category_scores_gemma":[0.0014227234,0.0003023118,0.00073474477,0.002505009,0.0004785344,0.00078400073,0.0005038538,0.0018594938,0.00088221504],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018151184,0.00009429256,0.00059940544,0.012094601,0.0003207364,0.00017568957,0.000023809038,0.00027597757,0.00066992437,0.0006845941,0.011960719,0.9729187],"study_design_scores_gemma":[0.00035184584,0.000539892,0.012370733,0.014492917,0.0020339084,0.0044320202,0.0001576505,0.0006285894,0.0014675297,0.0026618196,0.9607601,0.00010292636],"about_ca_topic_score_codex":0.0017780843,"about_ca_topic_score_gemma":0.0032982358,"teacher_disagreement_score":0.0032693862,"about_ca_system_score_codex":0.00052409555,"about_ca_system_score_gemma":0.0010078177,"threshold_uncertainty_score":0.0058596134},"labels":[],"label_agreement":null},{"id":"W2091115695","doi":"10.3816/clm.2009.n.008","title":"Prognostic Relevance of 6q Deletion in Waldenström's Macroglobulinemia: A Multicenter Study","year":2009,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre; University Health Network","funders":"Leukemia and Lymphoma Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Clinical significance; Fluorescence in situ hybridization; Macroglobulinemia; Waldenstrom macroglobulinemia; Internal medicine; Gastroenterology; Biology; Monoclonal gammopathy of undetermined significance; Abnormality; In situ hybridization; Pathology; Medicine; Multiple myeloma; Antibody; Chromosome; Immunology; Genetics; Gene; Monoclonal; Gene expression; Lymphoma; Monoclonal antibody","score_opus":0.035326875047981744,"score_gpt":0.382843954020466,"score_spread":0.34751707897248424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091115695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995766,0.00013338882,0.000026913165,0.000027801689,0.00000308454,0.0000092682685,0.000121716614,0.000001344537,0.00009990303],"genre_scores_gemma":[0.9994905,0.00006463782,0.000045218814,0.00001959315,0.000018606357,0.000013289743,0.00028103672,0.0000022486452,0.000064976455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988651,0.0005040764,0.000082290164,0.00030185006,0.0001123175,0.00013434737],"domain_scores_gemma":[0.9983198,0.0003528473,0.00051564863,0.0001736184,0.00023824292,0.00039983063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020173583,0.0007280452,0.00072020944,0.0009389696,0.0009905348,0.0008098535,0.00063316524,0.0006632392,0.0010345456],"category_scores_gemma":[0.0029165319,0.0004148222,0.000466887,0.0011529597,0.000801459,0.0007877042,0.0007308919,0.00047743157,0.0002536224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034051735,0.00019291279,0.9910964,0.000010093314,0.00023203909,0.0003255368,0.0002270213,0.00009397355,0.0019890359,0.000028323708,0.0001932306,0.0022063795],"study_design_scores_gemma":[0.00024888947,0.0007564562,0.9970522,0.0000050601934,0.00018423452,0.0007461719,0.00029531843,0.00014716444,0.00019527662,0.000030595525,0.00032901793,0.0000095734185],"about_ca_topic_score_codex":0.0027768314,"about_ca_topic_score_gemma":0.0020097597,"teacher_disagreement_score":0.0027768314,"about_ca_system_score_codex":0.00047253948,"about_ca_system_score_gemma":0.00043776422,"threshold_uncertainty_score":0.010668993},"labels":[],"label_agreement":null},{"id":"W2105407688","doi":"10.3816/clm.2005.n.034","title":"Evolving Role of Stem Cell Transplantation in Multiple Myeloma","year":2005,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Thalidomide; Melphalan; Multiple myeloma; Oncology; Transplantation; Internal medicine; Lenalidomide; Bortezomib; Prednisone; Hematopoietic stem cell transplantation; Surgery","score_opus":0.08757526195142284,"score_gpt":0.394048972723216,"score_spread":0.30647371077179314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105407688","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003330947,0.9992914,0.00004773655,0.00017594328,0.00013996086,0.0000015788203,0.0000050286753,0.0000021500332,0.00030283487],"genre_scores_gemma":[0.000306964,0.9988243,0.0001445937,0.00027045596,0.00022984404,0.0000027820759,0.000012469159,6.34525e-7,0.00020797082],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99967873,0.00006887544,0.00006280379,0.000053966993,0.00011377623,0.000021826441],"domain_scores_gemma":[0.9988368,0.0007279794,0.00013568756,0.000021034337,0.00022131245,0.000057114692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014542539,0.0008425596,0.0024499309,0.003102669,0.00034196238,0.0014690071,0.0010698151,0.0015744959,0.003372366],"category_scores_gemma":[0.0017071139,0.0003433748,0.0007474886,0.003772699,0.00070339604,0.0018824682,0.00071366614,0.0021884516,0.0015450013],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012589304,0.00006543433,0.0002243244,0.018713705,0.00017203519,0.0002744619,0.000039658797,0.00033020644,0.00070454617,0.0025851107,0.032017622,0.94474703],"study_design_scores_gemma":[0.00008127602,0.00013863991,0.0011488348,0.006970262,0.00043693537,0.0019680571,0.000073813404,0.0001295122,0.00027933824,0.0018253216,0.9869239,0.000024128492],"about_ca_topic_score_codex":0.0016847389,"about_ca_topic_score_gemma":0.004034698,"teacher_disagreement_score":0.003372366,"about_ca_system_score_codex":0.00093535724,"about_ca_system_score_gemma":0.0016369006,"threshold_uncertainty_score":0.011281729},"labels":[],"label_agreement":null},{"id":"W2106379961","doi":"10.3816/clm.2008.n.051","title":"Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment","year":2008,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Refractory (planetary science); Oncology; Doxorubicin; Internal medicine; Renal function; Chemotherapy; Materials science","score_opus":0.030798670057492043,"score_gpt":0.3048801949785689,"score_spread":0.27408152492107685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106379961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962759,0.0029417686,0.00011044459,0.00011984715,0.000017467808,0.000038514318,0.00008112821,0.000019740703,0.00039522751],"genre_scores_gemma":[0.9987087,0.0008107361,0.000109578985,0.00007173143,0.000032927564,0.000022501898,0.00009137557,0.000003510164,0.00014878584],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99982053,0.00007764836,0.000012379044,0.000031420386,0.000022107339,0.00003593855],"domain_scores_gemma":[0.9996389,0.000109009896,0.00008952128,0.00002765628,0.000013420593,0.00012149978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058812374,0.00037390718,0.0011592226,0.0002700707,0.00019819856,0.00039904338,0.00027222183,0.00034231434,0.0010284979],"category_scores_gemma":[0.0009181521,0.00017009804,0.0004651089,0.00039214027,0.00032435113,0.00048243266,0.00020473829,0.0008852354,0.00022421063],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54872066,0.0071119242,0.049251188,0.00063627237,0.0016027541,0.00073814095,0.00034139707,0.003698947,0.030466625,0.0002695252,0.0017331903,0.3554293],"study_design_scores_gemma":[0.24271713,0.38223085,0.33791292,0.0001632418,0.0029867094,0.0026029781,0.00033935154,0.010200606,0.014835347,0.00056687347,0.005338627,0.000105477826],"about_ca_topic_score_codex":0.0008502006,"about_ca_topic_score_gemma":0.0010383604,"teacher_disagreement_score":0.0011592226,"about_ca_system_score_codex":0.0006027648,"about_ca_system_score_gemma":0.00045894246,"threshold_uncertainty_score":0.0043733716},"labels":[],"label_agreement":null},{"id":"W2114319427","doi":"10.3816/clm.2006.n.030","title":"Late Clinically Silent Perforation of Intestinal Non-Hodgkin's Lymphoma","year":2006,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Positron emission tomography; Medicine; Perforation; Lymphoma; Chemotherapy; Radiology; Abscess; Nuclear medicine; Pathology; Surgery","score_opus":0.02568037654029906,"score_gpt":0.32988548373048077,"score_spread":0.3042051071901817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114319427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97284085,0.0083468035,0.0016080424,0.0016290788,0.00033575855,0.00007850434,0.00019024021,0.00017456092,0.014796191],"genre_scores_gemma":[0.9977259,0.00055572455,0.0002047862,0.00037007045,0.0004587746,0.000010524089,0.00010320549,0.000009664974,0.0005612205],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9996296,0.0000619824,0.00004450159,0.000047609832,0.00004553324,0.0001708069],"domain_scores_gemma":[0.99781346,0.00084692764,0.0003530326,0.00022062004,0.0001792086,0.0005866275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005132645,0.0008990505,0.0007079044,0.0014193428,0.0008147466,0.0012628122,0.0006761231,0.0024860152,0.0026650946],"category_scores_gemma":[0.0056678867,0.000446905,0.00044946987,0.00053261523,0.0009542179,0.0017152545,0.0008169085,0.0017984879,0.0011304747],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015587347,0.00015889869,0.12022808,0.00011007819,0.000018694676,0.86594325,0.000183985,0.00007776445,0.0024751017,0.00042709638,0.0008032717,0.008015022],"study_design_scores_gemma":[0.00013721675,0.000756617,0.06034773,0.000044529956,0.00004333954,0.93465614,0.0002294523,0.00028550054,0.0018429392,0.00033714282,0.0013022438,0.000017177177],"about_ca_topic_score_codex":0.00035404274,"about_ca_topic_score_gemma":0.00036310844,"teacher_disagreement_score":0.0026650946,"about_ca_system_score_codex":0.00066884863,"about_ca_system_score_gemma":0.00035007746,"threshold_uncertainty_score":0.008915663},"labels":[],"label_agreement":null},{"id":"W2118477722","doi":"10.3816/clm.2009.n.038","title":"Biomarkers and Prognosis in Malignant Lymphomas","year":2009,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Boehringer Ingelheim","keywords":"Hematology; Lymphoma; Medicine; Internal medicine; Follicular lymphoma; Oncology; Hodgkin lymphoma; Mantle cell lymphoma; Pathology","score_opus":0.032543491852764624,"score_gpt":0.33770214878561705,"score_spread":0.30515865693285243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118477722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9171807,0.07335748,0.000846551,0.00252566,0.00029869055,0.000022824375,0.00087998674,0.000060724233,0.0048274207],"genre_scores_gemma":[0.99298966,0.0053320616,0.0003829179,0.00015393736,0.00025075133,0.0000124167545,0.0004666412,0.0000048287275,0.00040682367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995888,0.0001396819,0.000066133005,0.00003992545,0.00009964363,0.000065855274],"domain_scores_gemma":[0.9981438,0.0005081527,0.000788387,0.00007452246,0.0002783051,0.00020685309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087712676,0.00037852873,0.0006204235,0.0014892316,0.0003668605,0.0014417034,0.00030425485,0.0007583459,0.00085204036],"category_scores_gemma":[0.004207365,0.00020533203,0.00024640054,0.0018318258,0.00027539043,0.00082516397,0.0003353402,0.0006580421,0.000332525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007082899,0.00006930747,0.9704133,0.000081135666,0.00012109948,0.0002996555,0.000044830445,0.0002494873,0.0010675156,0.0002482441,0.0010364699,0.02566052],"study_design_scores_gemma":[0.000051230567,0.0004702968,0.9823104,0.00013872677,0.00037350255,0.0027238894,0.0002499567,0.0015843224,0.0025306127,0.0020089606,0.0075310776,0.000026890591],"about_ca_topic_score_codex":0.00076375506,"about_ca_topic_score_gemma":0.0006470966,"teacher_disagreement_score":0.0014892316,"about_ca_system_score_codex":0.00045481315,"about_ca_system_score_gemma":0.00038802967,"threshold_uncertainty_score":0.0046387315},"labels":[],"label_agreement":null},{"id":"W2124433242","doi":"10.3816/clm.2009.n.019","title":"Bortezomib in Relapsed or Refractory Waldenström's Macroglobulinemia","year":2009,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; Queen Elizabeth II Health Sciences Centre; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Waldenstrom macroglobulinemia; Macroglobulinemia; Proteasome inhibitor; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine; Peripheral neuropathy; Lymphoma; Endocrinology; Biology","score_opus":0.1287236890803222,"score_gpt":0.4669914693417026,"score_spread":0.3382677802613804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124433242","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014411734,0.9992168,0.00003297783,0.00010626547,0.00009367839,0.000003783269,0.000014212346,0.0000032344433,0.00038497927],"genre_scores_gemma":[0.001523611,0.9976133,0.000100814024,0.00024001457,0.00014326474,0.0000072246316,0.00003819516,0.0000011005163,0.00033255105],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983513,0.00003460907,0.00004629236,0.000025772732,0.000043003594,0.000015143437],"domain_scores_gemma":[0.99966645,0.00015338956,0.000094617346,0.0000080947675,0.000052617354,0.000024750885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005628711,0.00066040084,0.0023730034,0.0021209104,0.00018464137,0.0006383172,0.00078737136,0.00065322855,0.003311379],"category_scores_gemma":[0.00086514064,0.00026311338,0.0005464632,0.0020773397,0.00035226764,0.0008122087,0.00045382357,0.0008391145,0.00094396673],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003138344,0.000051382816,0.00028319715,0.027218781,0.00029886575,0.00031289423,0.00003664583,0.00022199292,0.00095242565,0.0005818981,0.03138247,0.9383455],"study_design_scores_gemma":[0.0005314615,0.00046732876,0.00310074,0.013168961,0.0021361446,0.0043148547,0.00010403169,0.0001839984,0.0007427925,0.0008852544,0.97432816,0.000036231257],"about_ca_topic_score_codex":0.0010815329,"about_ca_topic_score_gemma":0.0034535169,"teacher_disagreement_score":0.003311379,"about_ca_system_score_codex":0.0005168811,"about_ca_system_score_gemma":0.0008537776,"threshold_uncertainty_score":0.011077642},"labels":[],"label_agreement":null}]}